RT Journal Article
SR Electronic
T1 Liver disease is a significant risk factor for cardiovascular outcomes - a UK Biobank study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.12.08.22283242
DO 10.1101/2022.12.08.22283242
A1 Roca-Fernandez, Adriana
A1 Banerjee, Rajarshi
A1 Thomaides-Brears, Helena
A1 Telford, Alison
A1 Sanyal, Arun
A1 Neubauer, Stefan
A1 Nichols, Thomas E
A1 Raman, Betty
A1 McCracken, Celeste
A1 Petersen, Steffen E
A1 Ntusi, Ntobeko AB
A1 Cuthbertson, Daniel J
A1 Lai, Michele
A1 Dennis, Andrea
A1 Banerjee, Amitava
YR 2022
UL http://medrxiv.org/content/early/2022/12/09/2022.12.08.22283242.abstract
AB Background Chronic liver disease (CLD) and cardiovascular diseases (CVD) share common risk factors; the former is associated with a two-fold greater incidence of CVD. With most CLD being preventable/modifiable, early identification of at high-risk individuals is crucial. Using data from the UK Biobank imaging sub-study, we tested the hypothesis that early signs of liver disease (measured by iron corrected T1-mapping (cT1)) is associated with an increased risk of major cardiovascular events.Methods Liver disease activity (cT1) and fat (PDFF) were measured using LiverMultiScan® from images acquired between January-2016 and February-2020 in the UK Biobank imaging sub-study. Multivariable Cox regression was used to explore associations between liver cT1 (MRI) and primary CVD outcomes (coronary artery disease, atrial fibrillation, embolism/vascular events, heart failure and stroke), as well as CVD hospitalisation and all-cause mortality. Other liver blood biomarkers (AST, ALT, AST/ALT ratio, FIB4), general metabolism biomarkers (CRP, HbA1c, systolic blood pressure (SBP), total cholesterol), and demographics were also included. Subgroup analysis was conducted in those without metabolic syndrome (MetS= at least 3 of these traits: a large waist, high triglycerides, low HDL cholesterol, increased SBP, or elevated HbA1c)Results 33,616 participants in the UK Biobank imaging sub-study (65 years, mean BMI 26kg/m2, mean HbA1c 35mmol/mol) had complete MRI liver data with linked clinical outcomes [median time to major CVD event onset: 1.4 years (range:0.002-5.1); follow-up: 2.5 years (range:1.1-5.2)]. Liver disease activity (cT1), but not liver fat (PDFF), was associated with a higher risk of any major CVD event [HR(CI) 1.14(1.03-1.26), p=0.008], AF [1.30 (1.12-1.5), p<0.001]; HF [1.30 (1.08 - 1.58), p=0.004]; CVD hospitalisation [1.27(1.18-1.387, p<0.001] and all-cause mortality [1.19(1.02-1.38), p=0.026]. FIB4 index, was associated with HF [1.06 (1.01 - 1.10)), p=0.007]. The risk of CVD hospitalisation was also independently associated with cT1 in individuals without MetS [1.26(1.13-1.4), p<0.001].Conclusion Liver disease activity, as measured with MRI-derived biomarker cT1, was independently associated with a higher risk of new onset CVD events and all-cause mortality. This association occurred even without pre-existing impairment of metabolic health and was independent of FIB4 or liver fat content. cT1 was identified as a major predictor of adverse CVD outcomes.Competing Interest StatementAdriana Roca-Fernandez, Rajarshi Banerjee, Helena Thomaides-Brears, Alison Telford and Andrea Dennis are employees from Perspectum Ltd. ACKNOWLEGDEMENTS: SN acknowledges support from the Oxford NIHR Biomedical Research Centre. BR is funded by the British Heart Foundation Oxford Centre of Research Excellence (RE/18/3/34214)Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee/IRB of Northwest Multi-Centre Research Ethics Committee (MREC) gave ethical approval for this work 11/NW/0382I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData Availability Statement The data analyzed in this study is subject to the following licenses/restrictions: Data belongs to UK Biobank. Requests to access these datasets should be directed to access{at}ukbiobank.ac.uk. https://www.ukbiobank.ac.uk/